State NADAC-plus-dispensing-fee floors are the binding-now PBM forcing function

One-line summary: While the federal CAA 2026 doesn't bite until 2028-29, a dozen states have already imposed hard cash floors under pharmacy reimbursement — NADAC + $10.05–$15 dispensing fees — in the commercial market, which is exactly where PBM spread lived; these are dated, in-force, dollar-denominated, and they bind two to three years before federal law does.

The insight

The PBM-reform conversation is dominated by federal action, and federal action is slow: the CAA 2026's remittance and bona-fide-service-fee provisions land in 2028 (Part D) and 2028-2029 (commercial). That timeline is why pbm-profit-pool-migration concludes the spread-compression bear case doesn't clear the bar through 2027.

But the states are already there, and they attack a different thing. A NADAC + dispensing-fee floor is not a transparency rule — it is a legal prohibition on reimbursing a pharmacy below acquisition cost. It converts the squeeze from a negotiation into an illegality, in force now, in the commercial book.

The squeeze it prohibits is quantified. Wholesalers price brand drugs to large chains at roughly 94% of WAC (a 6% sell-side discount) but cut GLP-1 discounts for smaller pharmacies to only 98% of WAC (2%) — while "PBMs' reimbursements to pharmacies typically average 96% of WAC or lower." So an independent buying at 98 and getting reimbursed at 96 dispenses below acquisition cost despite high volume. The NADAC-plus-dispensing-fee floor is precisely a legal prohibition on that gap.

The damage that produced the legislation: PBM reimbursement spreads contributed to over 1,200 independent pharmacy closures since 2013, particularly rural; NCPA reports "thousands of pharmacies shuttered their doors in 2024 and 2025," which is what "prompt[ed] state policymakers to accelerate legislation."

New Jersey's A. 1502 is the one to watch, because it attacks the relocation routes rather than the spread: it pairs a NADAC + $10.92 floor with a PBM fiduciary duty, an anti-affiliate-preference rule (no preferential reimbursement to affiliated pharmacies), and delinking of PBM compensation from rebates — i.e. it targets the CostVantage cost-plus route and the Cordavis benchmark route simultaneously. Passed the Assembly 2026-05-21; in Senate Commerce Committee.

Who bears the cost. Frier Levitt's read on incidence: the increased costs "are borne primarily by PBMs and health plans, reducing PBM profit margins and requiring plan sponsors to adjust pricing structures."

The state stack

From Frier Levitt's 2026 state PBM reform survey via 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration unless noted.

Evidence

All from 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.

• The margin arithmetic the floors prohibit — Drug Channels: wholesalers price brand drugs to large chains at ~94% of WAC but cut GLP-1 discounts for smaller pharmacies to only 98% of WAC; "PBMs' reimbursements to pharmacies typically average 96% of WAC or lower" — so many independents dispense below acquisition cost despite high volume.
• The damage — over 1,200 independent closures since 2013, particularly rural (Grokipedia: Pharmacy benefit management); NCPA: "thousands of pharmacies shuttered their doors in 2024 and 2025," which "prompt[ed] state policymakers to accelerate legislation" (⚠ search synthesis).
• Incidence — Frier Levitt: the increased costs "are borne primarily by PBMs and health plans, reducing PBM profit margins and requiring plan sponsors to adjust pricing structures."
• Timing vs federal — the CAA 2026 bites 2028 (Part D) / 2028-2029 (commercial), per Mintz. The state floors above bind now, in commercial.

Implications

• This is the forcing function with a date on it. If the spread-compression thesis is going to work anywhere before 2028, it works here — dated, dollar-denominated, in-force, and in the commercial book where the spread lived. It is a genuinely better forcing function than the federal stack that drug-pricing-reform-pbm-spread-compression was built on.
• Risk side: CVS/CI/UNH — Frier Levitt puts the incidence on PBMs and health plans. NJ A. 1502 is the sharpest because it closes the relocation routes (pbm-profit-pool-migration) at the same time.
• ⚠ Candidate beneficiary side (NOT established — see below): wholesalers serving independents — MCK (Health Mart, "nearly 4,000 high-performing, locally owned independent community pharmacies") and COR (Cencora, Good Neighbor Pharmacy, "more than 4,000 community pharmacy owners" as of July 2025). CAH has no independent-franchise figure in this pass.
• Arkansas HB 1150 is the tail — a first-in-nation ban on PBMs owning pharmacies, enjoined since 2025-07-28. If it survives challenge it is the state-level version of the divestiture risk that actually threatens the specialty pool.

Contradictions / tensions

• ⚠ The MCK/COR beneficiary link is an unverified inferential leap, and the autoresearch says so explicitly. "No source in this pass quantifies wholesaler earnings sensitivity to independent-pharmacy count, and no MCK/COR/CAH management commentary from the past 30 days surfaced connecting state NADAC floors to their outlook." The margin asymmetry (94% vs 98% of WAC) and the franchise counts are cited, but combining them into "independent survival is worth disproportionately more to MCK/COR" is an unverified synthesis step. Do not emit a signal on this without sizing it.
• ⚠ Counter-evidence actively cuts against the beneficiary leg, and it is strong. (a) The Big Three wholesalers have spent over $16 billion since 2013 acquiring or partnering with physician-practice MSOs, because traditional distribution is thin-margin ("buy low, sell high, collect early, pay late") and clinical services are "higher-margin... reducing dependency on distribution spreads" — their own stated strategy points away from retail distribution. (b) Both franchise networks are losing Part D preferred status: McKesson's Health Mart Atlas participates directly in only two HCSC plans, and Cencora's Elevate members "will not be preferred in any major plan for 2026" — a ninth consecutive year. Independents are walking away from Part D networks at the same moment state law improves their commercial economics.
• No listed pure-play expression exists on the beneficiary side. Navitus, Capital Rx, AffirmedRx and Cost Plus are private; Walgreens is no longer listed; Rite Aid is gone. The beneficiary side of drug-pricing-reform-pbm-spread-compression may simply have no clean ticker — which is itself a finding.
• The state stack is heterogeneous — different markets (commercial vs Medicaid managed care vs state employee), different effective dates, several still pending. Aggregate impact is unsized.
• Arkansas HB 1150 is enjoined and may not survive.

Open questions

• Does any MCK/COR/CAH management commentary connect state NADAC floors to outlook? Nothing in the past 30 days surfaced.
• What is wholesaler earnings sensitivity to independent-pharmacy count? Unquantified anywhere — the gating question for the beneficiary leg.
• Do the state floors survive ERISA preemption challenges? (Arkansas HB 1150 is already enjoined on other grounds.)
• What share of CVS/CI/UNH commercial book sits in the states with in-force floors?

Valuation snapshot

Last refreshed 2026-07-20 (pre-open; marks are the Friday 2026-07-17 close, markets closed over the weekend). Price fills tagged twelvedata.

✎ All six of this page's suggested tickers are now marked — today's Twelve Data pull is broader than the 07-17 run's 77-symbol set, so MCK, COR, CAH, CVS, CI and UNH carry prices this run where they were blank before. Given the beneficiary-leg caveats below, the marks are context — the binding constraint on this page is the unestablished wholesaler-beneficiary link, not price availability.

Sector read-across from the pull: XLF $56.75 (+0.34%) — directional context for a green-financials day only; managed care is not in XLF and no wholesaler proxy was pulled.

Forward-looking outcomes (12-month)

Bull case (for the spread-compression thesis working — expressed on the risk side) — the state stack keeps compounding and NJ A. 1502 clears the Senate: this is the forcing function with a date on it, and that is what distinguishes it from the federal stack. A dozen states have already imposed hard cash floors — NADAC + $10.05 (California, Oct 2025, all in-network pharmacies, plus 100% rebate pass-through and equal reimbursement for non-affiliated pharmacies), + $14.14 (Connecticut), + $15 (Montana), + $10.64 (Kentucky) — in the commercial book, which is exactly where PBM spread lived. A NADAC-plus-dispensing-fee floor is not a transparency rule; it is a legal prohibition on reimbursing below acquisition cost. It converts the squeeze from a negotiation into an illegality, now. Implied price: unsized — no marks. Cited: 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.

Base case — the floors bind, the aggregate impact stays unsized, and nobody can trade it cleanly: the state stack is heterogeneous — different markets (commercial vs Medicaid managed care vs state employee), different effective dates, several still pending — and no source aggregates the impact. The margin arithmetic it prohibits is real and quantified (wholesalers price brand drugs to large chains at ~94% of WAC but cut GLP-1 discounts for smaller pharmacies to only 98% of WAC, while "PBMs' reimbursements to pharmacies typically average 96% of WAC or lower" — so independents dispense below acquisition cost despite high volume), but the translation from that arithmetic to any listed company's EPS is not made anywhere. Implied price: unsized. Cited: 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.

Bear case (for this page's beneficiary leg specifically) — the wholesaler thesis is contradicted, not merely unproven: two pieces of counter-evidence, and they are strong. (a) The Big Three have spent over $16 billion since 2013 acquiring physician-practice MSOs because traditional distribution is thin-margin — "buy low, sell high, collect early, pay late" — and clinical services are "higher-margin... reducing dependency on distribution spreads." Their own stated strategy points away from retail distribution. (b) Both franchise networks are losing Part D preferred status: McKesson's Health Mart Atlas participates directly in only two HCSC plans, and Cencora's Elevate members "will not be preferred in any major plan for 2026" — a ninth consecutive year. Independents are walking away from Part D networks at the same moment state law improves their commercial economics. Implied price: unsized. Cited: 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.

Currently undervalued vs base case? No view — and on the beneficiary side this page explicitly instructs against forming one.

• Risk side (CVS/CI/UNH): no mark, but the direction is sourced. Frier Levitt places incidence on PBMs and health plans. Note this cuts against the sibling verdict in pbm-profit-pool-migration (which concludes spread compression doesn't clear the bar through 2027) — and the two are reconcilable precisely because they are about different instruments: federal transparency rules miss the pool, state cash floors don't. That tension is the most valuable thing across the pair, and it is recorded rather than resolved.
• Beneficiary side (MCK/COR/CAH): No — do not size. The research is unambiguous: "⚠ The MCK/COR beneficiary link is an unverified inferential leap, and the autoresearch says so explicitly. No source in this pass quantifies wholesaler earnings sensitivity to independent-pharmacy count, and no MCK/COR/CAH management commentary from the past 30 days surfaced connecting state NADAC floors to their outlook... combining them into 'independent survival is worth disproportionately more to MCK/COR' is an unverified synthesis step. Do not emit a signal on this without sizing it." And unlike most gaps in this wiki, this one has active counter-evidence pointing the other way (the $16B MSO pivot; the Part D preferred-status losses).

A finding worth more than a position: "No listed pure-play expression exists on the beneficiary side." Navitus, Capital Rx, AffirmedRx and Cost Plus are private; Walgreens is no longer listed; Rite Aid is gone. The beneficiary side of drug-pricing-reform-pbm-spread-compression may simply have no clean ticker — which is itself a finding, and it is the honest reason this page stays a risk-side lens rather than a long idea.

Catalyst path:

• MCK Q1 FY2027 (early August) / COR Q3 FY2026 (early August) earnings — the gate for the beneficiary leg: does any management commentary connect state NADAC floors to outlook? Nothing in the prior 30 days did.
• New Jersey A. 1502 Senate Commerce Committee action — passed the Assembly 2026-05-21. The sharpest instrument in the stack because it targets the cost-plus and affiliate-benchmark relocation routes at once.
• Arkansas HB 1150 appeal — enjoined since 2025-07-28. If it survives, it is the state-level version of the divestiture risk that actually threatens the specialty pool.
• ERISA preemption challenges to the state floors — the systemic risk to this entire concept; unresolved.

Related

• pbm-profit-pool-migration — why federal transparency rules miss, and what NJ A. 1502 targets
• drug-pricing-reform-pbm-spread-compression — the hypothesis this re-bases
• unh
• legislative-divergence-base-rate